Response Genetics, Inc.  

(Public, NASDAQ:RGDX)   Watch this stock  
Find more results for Sam Chawla�
0.000 (0.00%)
Mar 31 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.44 - 0.47
52 week 0.25 - 1.56
Open 0.44
Vol / Avg. 35,700.00/184,555.00
Mkt cap 16.68M
P/E     -
Div/yield     -
EPS -0.65
Shares 38.78M
Beta 0.72
Inst. own 44%
Mar 31, 2015
Q4 2014 Response Genetics Inc Earnings Call
Mar 31, 2015
Q4 2014 Response Genetics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -81.61% -40.50%
Operating margin -75.13% -40.13%
EBITD margin - -36.93%
Return on average assets -101.50% -46.30%
Return on average equity -411.68% -307.49%
Employees 109 -
CDP Score - -


1640 Marengo St Fl 7th
LOS ANGELES, CA 90033-1057
United States - Map
+1-323-2243900 (Phone)
+1-323-2243096 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Response Genetics, Inc. is a life science company. The Company is engaged in the research, development, marketing and sale of pharmacogenomics-clinical diagnostic tests for cancer. The Company uses its technologies that enable the Company to extract ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) from tumor specimens that are stored as formalin-fixed and paraffin-embedded (FFPE) specimens and to analyze genetic information contained in these tissues for each patient. The Company�s platforms include analysis of single biomarkers using the polymerase chain reaction method as well as global gene interrogation using microarray methods and fluorescence in situ hybridization (FISH) from paraffin or frozen tissue specimens. The Company primarily sells ResponseDX diagnostic testing products and provides pharmacogenomic clinical trial testing services to pharmaceutical companies in the United States, Asia and Europe.

Officers and directors

Thomas A. Bologna Chairman of the Board, Chief Executive Officer
Age: 66
Bio & Compensation  - Reuters
Kevin R. Harris Chief Financial Officer, Vice President
Age: 45
Bio & Compensation  - Reuters
Stephanie H. Astrow Ph.D. Vice President - Research & Development
Age: 52
Bio & Compensation  - Reuters
Adanech Getachew General Counsel
Age: 37
Bio & Compensation  - Reuters
Kirk K. Calhoun Lead Independent Director
Age: 70
Bio & Compensation  - Reuters
Michael Serruya Director
Age: 49
Bio & Compensation  - Reuters
Sam Chawla Independent Director
Age: 39
Bio & Compensation  - Reuters
David R. Schreiber Independent Director
Bio & Compensation  - Reuters
Richard A. Van Den Broek Independent Director
Age: 48
Bio & Compensation  - Reuters